Adenocarcinoma of prostate | Neoplasm Metastasis regional Absent | Distant metastasis Absent | TNM clinical staging | Disease Severe Biopsy | Gleason score | Prostate specific antigen measurement
Item
histologic proof of prostatic adenocarcinoma without evidence of regional and/or distant metastasis, clinical stage t1c, t2 or t3 with high grade disease (gleason's 7- 10) on initial biopsy, or psa greater than 10 ng/ml with any stage or gleason score.
boolean
C0007112 (UMLS CUI [1])
C0027627 (UMLS CUI [2,1])
C0205147 (UMLS CUI [2,2])
C0332197 (UMLS CUI [2,3])
C1269798 (UMLS CUI [3,1])
C0332197 (UMLS CUI [3,2])
C3258246 (UMLS CUI [4])
C0012634 (UMLS CUI [5,1])
C0205082 (UMLS CUI [5,2])
C0005558 (UMLS CUI [5,3])
C3203027 (UMLS CUI [6])
C0201544 (UMLS CUI [7])
Bone scan Negative | CT of abdomen Negative | CT of Pelvis Negative
Item
recent (equal to or less than 1 month prior to study entry) negative bone scan and ct scan of abdomen/pelvis.
boolean
C0203668 (UMLS CUI [1,1])
C1513916 (UMLS CUI [1,2])
C0412620 (UMLS CUI [2,1])
C1513916 (UMLS CUI [2,2])
C0412628 (UMLS CUI [3,1])
C1513916 (UMLS CUI [3,2])
Life Expectancy
Item
life expectancy of at least 10 years.
boolean
C0023671 (UMLS CUI [1])
Indication Radical prostatectomy | Zubrod Performance Status
Item
appropriate surgical candidate for radical prostatectomy and a performance status of equal to or less than 2 (zubrod scale).
boolean
C3146298 (UMLS CUI [1,1])
C0194810 (UMLS CUI [1,2])
C3714786 (UMLS CUI [2])
Absolute neutrophil count Peripheral blood | Platelet Count measurement | Serum total bilirubin measurement | Alanine aminotransferase measurement | Creatinine measurement, serum
Item
patients should have adequate bone marrow function defined as an absolute peripheral granulocyte count equal to or greater than 1,500 and platelet count of equal to or greater than 100,000, adequate hepatic function with a bilirubin equal to or less than 1.5 mg per cent and sgpt less than 2 x the upper limits of normal, adequate renal function defined as serum creatinine equal to or less than 2.0 mg per cent.
boolean
C0948762 (UMLS CUI [1,1])
C0229664 (UMLS CUI [1,2])
C0032181 (UMLS CUI [2])
C1278039 (UMLS CUI [3])
C0201836 (UMLS CUI [4])
C0201976 (UMLS CUI [5])
Blood coagulation | Prothrombin time | Partial Thromboplastin Time measurement | Bleeding tendency Non-iatrogenic Absent | Anticoagulants Local
Item
patients must have normal coagulation profile (pt, ptt) and no history of substantial non-iatrogenic bleeding diatheses. use of anticoagulants is limited to local use only (for control of central line patency).
boolean
C0005778 (UMLS CUI [1])
C0033707 (UMLS CUI [2])
C0030605 (UMLS CUI [3])
C1458140 (UMLS CUI [4,1])
C0445141 (UMLS CUI [4,2])
C0332197 (UMLS CUI [4,3])
C0003280 (UMLS CUI [5,1])
C0205276 (UMLS CUI [5,2])
Informed Consent
Item
patients must sign an informed consent indicating that they are aware of the investigational nature of the study, in keeping with the policies of the institution.
boolean
C0021430 (UMLS CUI [1])
Hormone Therapy | Chemotherapy | Therapeutic radiology procedure | Immunotherapy | Investigational New Drugs
Item
previous or current hormonal treatment, chemotherapy, radiation therapy, immunotherapy or other investigational status drug within the past 4 weeks.
boolean
C0279025 (UMLS CUI [1])
C0392920 (UMLS CUI [2])
C1522449 (UMLS CUI [3])
C0021083 (UMLS CUI [4])
C0013230 (UMLS CUI [5])
Transrectal ultrasound Receive Unable
Item
unable to tolerate transrectal ultrasound.
boolean
C0373345 (UMLS CUI [1,1])
C1514756 (UMLS CUI [1,2])
C1299582 (UMLS CUI [1,3])
Radical prostatectomy Patient Inappropriate | Comorbidity Evaluation | Cause of Death Evaluation
Item
patients who are not appropriate surgical candidates for radical prostatectomy based on the evaluation of co-existent medical diseases and competing causes of death.
boolean
C0194810 (UMLS CUI [1,1])
C0030705 (UMLS CUI [1,2])
C1548788 (UMLS CUI [1,3])
C0009488 (UMLS CUI [2,1])
C1261322 (UMLS CUI [2,2])
C0007465 (UMLS CUI [3,1])
C1261322 (UMLS CUI [3,2])
Heart Diseases Uncontrolled | Liver diseases Uncontrolled | Kidney Diseases Uncontrolled | nervous system disorder Uncontrolled | Mental disorders Uncontrolled
Item
patients with uncontrolled cardiac, hepatic, renal or neurologic/psychiatric disorders are not eligible.
boolean
C0018799 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0023895 (UMLS CUI [2,1])
C0205318 (UMLS CUI [2,2])
C0022658 (UMLS CUI [3,1])
C0205318 (UMLS CUI [3,2])
C0027765 (UMLS CUI [4,1])
C0205318 (UMLS CUI [4,2])
C0004936 (UMLS CUI [5,1])
C0205318 (UMLS CUI [5,2])
HIV Seropositivity | Hepatitis B, Chronic | Hepatitis C, Chronic
Item
patients who are hiv positive or have chronic hepatitis b or c infections are not eligible (because of possible immune effects of these conditions).
boolean
C0019699 (UMLS CUI [1])
C0524909 (UMLS CUI [2])
C0524910 (UMLS CUI [3])
Primary immune deficiency disorder | Secondary immune deficiency disorder | Immunosuppressive Agents | Adrenal Cortex Hormones | Hydrocortisone U/day | Decreased immune responsiveness
Item
patients with a history of primary or secondary immunodeficiency or patients taking immunosuppressive drugs such as corticosteroids continuously for greater than 4 months [greater than 5 mg hydrocortisone/day] are ineligible. (the experimental treatment being evaluated in this protocol depends on an intact immune system. patients who have a decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities.)
boolean
C0398686 (UMLS CUI [1])
C0398795 (UMLS CUI [2])
C0021081 (UMLS CUI [3])
C0001617 (UMLS CUI [4])
C0020268 (UMLS CUI [5,1])
C0456683 (UMLS CUI [5,2])
C0863087 (UMLS CUI [6])